Syntara’s (ASX: SNT) AZALOX trial clears first safety hurdle and advances to final 200 mg cohort

Syntara Limited (ASX: SNT) has advanced the Phase 1b AZALOX clinical trial into its final dose-escalation cohort after an independent safety board cleared the study to evaluate amsulostat at 200 mg twice daily alongside 5-Azacitidine. The initial cohort, which received amsulostat at 150 mg twice daily, recorded no dose-limiting toxicities and no new adverse events attributed to the investigational drug. All 10 participating German clinical centres have been activated, with patients already pre-registered for the higher-dose cohort. Preliminary results from the completed Phase 1b dose-escalation component remain scheduled for the fourth quarter of 2026. The central question is whether this encouraging safety progression can be followed by early clinical evidence strong enough to establish myelodysplastic neoplasms as a credible second major development pathway for amsulostat.

Why does clearance to the 200 mg AZALOX cohort reduce clinical execution risk without proving efficacy?

The Drug Safety Monitoring Board’s decision allows Syntara Limited and the study investigators to move directly into the final planned Phase 1b dose cohort. That is a meaningful operational milestone because early-stage combination studies must first establish whether adding an experimental therapy to an existing treatment produces unacceptable toxicity or creates safety interactions that prevent further development.

The absence of dose-limiting toxicities in the 150 mg cohort therefore removes one immediate barrier. It does not establish that amsulostat is effective against high-risk myelodysplastic neoplasms or chronic myelomonocytic leukaemia, but it supports continued evaluation at the higher planned dose.

Patients in the final cohort will receive amsulostat at 200 mg twice daily together with 5-Azacitidine. The Phase 1b component is intended to determine the combination’s safety profile and select a recommended dose for Phase 2. Subject to the outcome of the 200 mg cohort and a further safety review, AZALOX is expected to progress into a Phase 2 component involving approximately 30 patients.

The distinction between safety progression and clinical validation is particularly important for investors. Dose escalation demonstrates that the study remains executable. A genuine therapeutic signal will require evidence involving blood-cell production, transfusion requirements, disease response and other predefined clinical outcomes.

Nevertheless, completing the first cohort without an identified dose-limiting toxicity gives Syntara a cleaner path into the more informative portion of the study. The higher dose should help determine whether sufficient drug exposure can be achieved while maintaining an acceptable tolerability profile alongside 5-Azacitidine.

How could AZALOX broaden amsulostat from myelofibrosis into a larger blood-cancer platform?

Amsulostat, also known as SNT-5505 and previously as PXS-5505, is Syntara Limited’s orally administered pan-lysyl oxidase inhibitor. The company’s primary development strategy has focused on targeting extracellular matrix dysfunction and fibrosis associated with blood cancers.

The drug has already completed a Phase 2a study in myelofibrosis, where it was assessed in combination with ruxolitinib. Syntara previously reported that eight of 11 evaluable patients achieved at least a 50% reduction in total symptom score at week 24 or later, while four of nine evaluable patients achieved at least a 25% reduction in spleen volume. Those company-reported results provided the basis for regulatory engagement and further development planning, although the study was small and open label.

Amsulostat has received United States Food and Drug Administration Fast Track and Orphan Drug designations for myelofibrosis, as well as clearance under an Investigational New Drug application. Syntara has also reported positive feedback from a Type C meeting supporting the proposed design of an approximately 100-patient, placebo-controlled Phase 2b myelofibrosis study. The company currently describes amsulostat as having completed Phase 2a development in myelofibrosis, while two studies in myelodysplastic neoplasms are recruiting.

AZALOX matters because it tests whether the biological approach can extend beyond a single blood-cancer indication. Myelofibrosis and myelodysplastic neoplasms are clinically distinct diseases, but both can involve disrupted bone-marrow function, impaired blood-cell production and abnormalities within the extracellular environment.

Success in myelodysplastic neoplasms would therefore strengthen the argument that amsulostat is more than a single-indication drug. It could become the foundation of a broader haematology development platform, potentially increasing its strategic relevance to larger pharmaceutical companies seeking differentiated combination therapies.

The opportunity remains conditional. Clinical activity observed in myelofibrosis cannot be assumed to transfer into another disease, particularly when amsulostat is being combined with a different standard treatment. AZALOX must establish its own safety, dose and efficacy evidence.

Why do 10 activated German sites matter for Syntara’s Q4 2026 AZALOX timeline?

Clinical-site activation is more than an administrative detail in a small biotechnology study. Recruitment delays are one of the most common reasons early-stage readouts move beyond their original schedules, especially in trials involving narrowly defined patient populations and competing studies.

Syntara reported that all 10 participating German centres are now initiated and open for recruitment. Sites had already been pre-screening potential participants while awaiting the independent safety review, and patients have been pre-registered for the 200 mg cohort.

That preparation reduces the gap between receiving dose-escalation approval and enrolling the next participants. It also supports management’s expectation that preliminary Phase 1b results can be released during the fourth quarter of 2026.

The recruitment footprint has become slightly broader than initially outlined. When AZALOX commenced in July 2025, Syntara referred to the first of nine planned German centres. The latest announcement confirms that 10 centres are now active, potentially expanding access to eligible patients and reducing dependence on any single hospital.

AZALOX is being conducted through the German MDS Study Group under the sponsorship of Heidelberg University, working with the Coordination Centre for Clinical Studies Heidelberg. German Cancer Aid is providing financial support.

This external sponsorship and grant backing are strategically useful for Syntara. They allow the company to expand the clinical evidence surrounding amsulostat without carrying the full cost and operational burden that would ordinarily accompany a multicentre European study.

The structure does not remove development risk, but it improves capital efficiency. For a company with several active clinical programmes, non-dilutive support can preserve funding for regulatory work, manufacturing, intellectual property and company-sponsored studies.

What is the scientific and commercial logic behind combining amsulostat with 5-Azacitidine?

The AZALOX programme is based on preclinical research suggesting that combining amsulostat with a hypomethylating agent may help reactivate red blood cell and platelet production. The clinical study is assessing whether that biological effect can translate into reduced dependence on blood transfusions and a lower risk of progression to acute myeloid leukaemia.

The combination strategy is commercially relevant because 5-Azacitidine is already used in the treatment pathway for higher-risk myelodysplastic neoplasms. Rather than attempting to replace an established therapy immediately, Syntara is evaluating whether amsulostat can improve outcomes when added to an existing treatment backbone.

An add-on strategy can offer a more practical development route when the investigational drug has a differentiated mechanism and a tolerability profile compatible with combination treatment. Physicians may be more willing to incorporate a new agent when it enhances an established regimen without introducing prohibitive toxicity or operational complexity.

However, combination development also raises the evidence threshold. The study must eventually demonstrate that any improvement is attributable to the addition of amsulostat rather than the underlying activity of 5-Azacitidine, patient selection or natural variation in a small cohort.

The current Phase 1b study is not designed to settle that question. Its immediate purpose is dose selection and safety. Preliminary signs involving blood counts, transfusion requirements or disease response could still influence market sentiment, but stronger conclusions would require the Phase 2 component and potentially later controlled studies.

The most valuable Q4 outcome would therefore combine acceptable safety at 200 mg with early biological or clinical observations that justify moving quickly into the approximately 30-patient expansion stage.

How do AZALOX and the Australian MESSAGE study create two distinct routes into MDS?

Syntara is not relying exclusively on a single myelodysplastic neoplasms study. Alongside AZALOX, the Australasian Leukaemia & Lymphoma Group is leading the Australian MDS05/D3 MESSAGE trial.

MESSAGE is evaluating amsulostat with ASTX727, an oral hypomethylating therapy, in patients with transfusion-dependent low and intermediate-risk myelodysplastic neoplasms. The study remains in recruitment for its initial dose-escalation cohort, with preliminary results expected during the first half of 2027.

The two programmes address different patient populations and treatment settings. AZALOX focuses on high-risk myelodysplastic neoplasms and chronic myelomonocytic leukaemia using 5-Azacitidine, while MESSAGE focuses on transfusion-dependent patients with lower-risk disease using an oral treatment combination.

This creates two separate opportunities to test the underlying therapeutic concept. Amsulostat could potentially demonstrate value in more advanced disease by complementing an established injectable hypomethylating agent, or in lower-risk disease by supporting blood-cell production and reducing transfusion dependence.

Running complementary studies also provides strategic protection. If one setting produces limited activity, the other may still identify a responsive patient group or a more suitable treatment combination.

The approach comes with additional complexity. Different risk categories, combination partners and study designs mean the results cannot simply be pooled. Syntara will need to show that each programme has a clear development rationale and that funding can be prioritised toward the most convincing clinical opportunity.

If both studies produce encouraging signals, the combined dataset could materially strengthen amsulostat’s partnering profile. It would show that independent academic groups in Germany and Australia had evaluated the drug across distinct myelodysplastic neoplasms populations.

What does Syntara Limited’s latest share price imply about confidence in the clinical pipeline?

The latest delayed market data available before publication placed Syntara shares at approximately A$0.024, giving the company a market capitalisation of about A$47 million. The stock was trading within a recently reported 52-week range of A$0.019 to A$0.066.

The current price is around 11% below the A$0.027 issue price used for Syntara’s recent share purchase plan. The company raised approximately A$8 million through an institutional placement and about A$840,000 through the subsequent share purchase plan, bringing combined gross proceeds to approximately A$8.84 million. Syntara indicated that the placement proceeds were expected to extend its cash runway into the third quarter of 2027.

That valuation suggests investors continue to apply a considerable discount for clinical, regulatory and commercialisation risk despite the company’s expanding data pipeline. The funding reduced immediate balance-sheet pressure, but it did not remove uncertainty surrounding later-stage trial costs, partnership timing or the probability of eventual approval.

The latest AZALOX milestone is constructive because it protects the Q4 catalyst and expands the number of active clinical programmes capable of generating value. However, an early safety clearance alone may not be sufficient to produce a sustained rerating.

A stronger market response would probably require evidence that the 200 mg combination is tolerable, that the trial can advance into Phase 2 without delay and that preliminary patient observations support the proposed biological mechanism.

Syntara’s relatively modest market value means a convincing clinical signal could have a meaningful valuation impact. The same sensitivity also works in reverse, as delays, inconclusive results or additional capital requirements could place renewed pressure on sentiment.

What evidence would turn the Q4 2026 AZALOX readout into a genuine valuation catalyst?

The first requirement is completion of the 200 mg cohort without safety findings that prevent the dose from advancing. Confirmation of a recommended Phase 2 dose would convert the current dose-escalation decision into a more substantive development milestone.

The second requirement is evidence that recruitment and site execution remain aligned with the expected timeline. Having 10 centres activated and patients pre-registered is encouraging, but the company must still complete dosing, follow-up and safety review before releasing a meaningful dataset.

The third requirement is an early indication that the treatment may be affecting disease biology or patient outcomes. Changes in red blood cell or platelet production, transfusion requirements and disease-response measures would be particularly relevant to the scientific rationale described by the investigators.

Small Phase 1b cohorts can produce volatile and difficult-to-interpret results. Any early efficacy observations should therefore be treated as hypothesis-generating rather than definitive. Consistency across patients and alignment with the expected mechanism would be more persuasive than a single exceptional response.

Investors will also look for confirmation that AZALOX can proceed promptly into its approximately 30-patient Phase 2 component. A clear transition plan, continued recruitment capacity and sufficient drug supply would indicate that Syntara and its academic partners are prepared to build on the Phase 1b findings.

Finally, the readout will be assessed alongside Syntara’s wider clinical and funding position. Progress in myelofibrosis, the MESSAGE trial and the company’s other drug candidates may increase partnering leverage, but management will still need to prioritise capital toward the programmes producing the strongest evidence.

Can Syntara convert a cleaner AZALOX pathway into a broader amsulostat development story?

The July 20 update improves the immediate outlook for AZALOX. The first cohort completed its planned dose stage without dose-limiting toxicities, the independent board approved escalation, all 10 German sites are open and the Q4 2026 preliminary data target remains intact.

What remains unresolved is whether amsulostat can produce clinically meaningful activity in high-risk myelodysplastic neoplasms and chronic myelomonocytic leukaemia when combined with 5-Azacitidine. The current milestone establishes permission to continue, not proof that the programme will succeed.

The next measurable test is completion of the 200 mg cohort and selection of a Phase 2 dose. A clean safety outcome accompanied by coherent early biological or clinical signals would strengthen the rationale for the 30-patient expansion and broaden the strategic value of amsulostat beyond myelofibrosis.

The investment thesis would strengthen further if AZALOX and MESSAGE produce complementary evidence across higher-risk and lower-risk disease populations. It would weaken if the higher dose creates tolerability limitations, recruitment slows or early observations fail to support the proposed mechanism.

Syntara has successfully moved AZALOX past its first clinical gate. The Q4 readout must now demonstrate whether that progress is simply procedural or the beginning of a commercially meaningful second blood-cancer opportunity.

What are the key takeaways from Syntara’s AZALOX Phase 1b dose-escalation milestone?

• Syntara Limited has completed the first AZALOX dose cohort evaluating amsulostat with 5-Azacitidine in high-risk myelodysplastic neoplasms and chronic myelomonocytic leukaemia.
• No dose-limiting toxicities or new adverse events attributed to amsulostat were observed in the initial 150 mg twice-daily cohort.
• An independent Drug Safety Monitoring Board has approved escalation to the final Phase 1b cohort using amsulostat at 200 mg twice daily.
• All 10 participating German clinical sites are activated, with patients pre-registered for the higher-dose cohort.
• Preliminary results from the completed Phase 1b dose-escalation component remain expected during the fourth quarter of 2026.
• Subject to safety clearance, AZALOX is expected to move into a Phase 2 component involving approximately 30 patients.
• The programme could expand amsulostat beyond its established myelofibrosis development pathway into a second significant blood-cancer indication.
• The parallel Australian MESSAGE study will evaluate amsulostat in a different myelodysplastic neoplasms population, with preliminary results anticipated during the first half of 2027.
• Syntara’s recent financing has improved its runway, although future valuation remains closely tied to clinical evidence and partnership progress.
• The decisive Q4 test will be whether acceptable safety at 200 mg is accompanied by early observations supporting the combination’s biological and clinical rationale.